CureDuchenne Ventures Invests $1 Million in Entos Pharmaceuticals for Duchenne Gene Therapy
NEWPORT BEACH, Calif. and EDMONTON, AB, May 22, 2025 – CureDuchenne Ventures today announced an initial $1 million investment in Entos Pharmaceuticals Inc. (Entos). This funding will enable Entos to develop a muscle-targeting therapeutic that delivers full-length dystrophin for Duchenne muscular dystrophy (DMD), utilizing its non-viral, redosable Fusogenix PLV delivery platform.
Entos’ Fusogenix PLV platform offers a novel approach for intracellular delivery of genetic medicines, aiming to overcome limitations of current viral methods, including pre-existing immunity and re-dosing challenges.
“We are very excited by the potential of Entos Pharmaceuticals’ technology, which can deliver full-length dystrophin and allow for redosing, addressing key challenges with current AAV-based approaches,” said Debra Miller, founder and CEO of CureDuchenne. This investment highlights CureDuchenne’s commitment to catalyzing transformative treatments for DMD.
John Lewis, CEO of Entos Pharmaceuticals, emphasized that the Fusogenix PLV platform enables “safe, effective, and redosable delivery of full-length functional genes… a real game-changer” for people with DMD.
Entos will present details about their platform and Duchenne plans at the CureDuchenne 2025 FUTURES National Conference on May 23.
Source:
https://entospharma.com/news-%26-media/f/entos-to-develop-dystrophin-therapy-for-dmd-with-cureduchenne
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related Services
-
AAV GMP Manufacturing
-
AAV Packaging – Research Grade
Comprehensive AAV Solutions, From Discovery to Delivery
-
AAV Analytical Services
Comprehensive AAV Solutions, From Discovery to Delivery
-
AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder
-
AAV Library Service
At PackGene, we offer a comprehensive range of AAV library services designed to advance your gene therapy research. Our expertise in AAV library creation and screening allows us to provide solutions tailored to your specific needs, enhancing gene delivery specificity and efficiency while minimizing off-target effects and bypassing innate immune responses.